WALTHAM, Mass.--(EON: Enhanced Online News)--Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer will present a corporate update at the upcoming 35th Annual J.P. Morgan Healthcare Conference on Thurday, January 12, 2017 at 10:30 a.m. PT in San Francisco.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals seeks to improve treatment and outcomes for patients with cancer by designing and developing innovative kinase inhibitor therapies that address key drug resistance mechanisms. Deciphera’s unique approach leverages its deep understanding of kinase biology to develop a robust pipeline of tumor-targeted and immuno-targeted product candidates that potentially improve the quality, rate and durability of response to treatment. Deciphera’s innovative switch control platform enables the creation of tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immuno-kinases that suppress critical immune system regulators, such as macrophages. This two-pronged approach to kinase inhibition is a key advance over other methods of inhibiting kinases for the treatment of cancer.